Outcomes of Patients with Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer

Jen Ruei Chen, Ting Chang Chang, Hung Chun Fu, Hei Yu Lau, I. Hui Chen, Yu Min Ke, Yu Ling Liang, An Jen Chiang, Chia Yen Huang, Yu Chieh Chen, Mun Kun Hong, Yu Chi Wang, Kuo Feng Huang, Sheng Mou Hsiao, Peng Hui Wang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In the management of patients with advanced-stage pure endometrioid-type endometrial cancer (E-EC), such as positive lymph nodes (stage III) or stage IV, treatment options are severely limited. This article aims to investigate the outcome of women with FIGO III-IV E-EC (based on FIGO 2009 system). The retrospective cohort study, based on the Taiwanese Gynecologic Oncology Group (TGOG-2005), enrolled patients undergoing staging surgery to have a pathologically confirmed FIGO III-IV E-EC from 22-member hospitals between 1991 and 2010. This cohort included 541 patients (stage III, n=464; stage IV, n=77). Five-year overall survival (OS) was 70.4%. Median progression-free survival (PFS) was 43 months (range 0-258 months) and median OS was 52 months (range 1-258 months). Multivariate analysis showed that FIGO stage, >1/2 myometrial invasion (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.12-2.09; P=0.007), histological grade 3 (HR 2.0, 95% CI 1.47-2.75; P<0.001), and metastases of pelvic and para-aortic lymph nodes (PLN and PALN) (HR 2.75, 95% CI 1.13-6.72; P<0.001) were independent risk factors for PFS. FIGO stage, >1/2 myometrial invasion (HR 1.89, 95% CI 1.34-2.64; P<0.001), and histological grade 3 (HR 2.42, 95% CI 1.75-3.35; P<0.001) influenced OS. Complete dissection of PLN and PALN (HR 0.27, 95% CI 0.16-0.45; P<0.001, and HR 0.14, 95% CI 0.08-0.26; P<0.001) and the following paclitaxel-based therapy (HR 0.61, 95% CI 0.79-0.92; P=0.017, and HR 0.48; 95% CI 0.31-0.75; P=0.001) provided the better PFS and OS, respectively. In management of women with FIGO III-V E-EC, combination of complete staging surgery (complete dissection of PLN and PALN is included) and the following paclitaxel-based therapy could provide the better chance to survive. Patients with tumor >1/2 myometrial invasion and histological grade 3 are risky for disease-related mortality.

Original languageEnglish
Article numbere3330
JournalMedicine (United States)
Volume95
Issue number15
DOIs
Publication statusPublished - 2016 Apr 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Outcomes of Patients with Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer'. Together they form a unique fingerprint.

  • Cite this

    Chen, J. R., Chang, T. C., Fu, H. C., Lau, H. Y., Chen, I. H., Ke, Y. M., Liang, Y. L., Chiang, A. J., Huang, C. Y., Chen, Y. C., Hong, M. K., Wang, Y. C., Huang, K. F., Hsiao, S. M., & Wang, P. H. (2016). Outcomes of Patients with Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer. Medicine (United States), 95(15), [e3330]. https://doi.org/10.1097/MD.0000000000003330